GlassScriptPhysician profile
Devin J Welker
NPI 1255976858
$2,825.31
in general payments reported to CMS, 2019-2025
42 companies · $757 in 2025
The $757 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $197 · 2022: $482 · 2023: $620 · 2024: $769 · 2025: $757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,145.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $902.08 | 2021-2024 | |
| Lilly USA, LLC | $241.86 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $213.98 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $157.47 | 2022-2025 | Farxiga, Airsupra |
| Amgen INC. | $124.03 | 2023-2025 | Evenity, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.12 | 2021-2024 | Jardiance |
| Radius Health, INC. | $65.89 | 2025 | Tymlos |
| Insulet Corporation | $64.63 | 2023-2025 | Omnipod |
| Nestle Healthcare Nutrition INC. | $53.41 | 2022-2023 | |
| Tandem Diabetes Care, INC. | $49.57 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $48.47 | 2025 | Strensiq |
| Paratek Pharmaceuticals, INC. | $47.28 | 2023 | Nuzyra |
| Nalu Medical, INC. | $41.37 | 2023-2024 | Nalu Neurostimulation System |
| Merck Sharp & Dohme LLC | $41.00 | 2021-2024 | |
| Sanofi Pasteur INC. | $40.75 | 2023 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $37.43 | 2023-2024 | Veozah |
| Cranial Technologies, INC | $37.28 | 2022 | |
| Cequr Corporation | $35.94 | 2025 | Cequr Simplicity |
| Pfizer INC. | $35.48 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $34.29 | 2024 | Voquezna |
| Recordati_rare_diseases_inc. | $34.09 | 2025 | Isturisa |
| Lucid Diagnostics INC. | $30.90 | 2022-2024 | |
| Medtronic, INC. | $29.73 | 2025 | Minimed 780g |
| Madrigal Pharmaceuticals | $28.83 | 2025 | Rezdiffra |
| Corcept Therapeutics | $28.42 | 2025 | Korlym |
| Mannkind Corporation | $25.78 | 2024 | |
| Baxter Healthcare | $24.89 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.32 | 2025 | |
| Dexcom, INC. | $23.01 | 2025 | Dexcom G6 Transmitter |
| Saluda Medical Americas, INC. | $21.04 | 2024 | Evoke |
| Verity Pharmaceuticals INC. | $21.01 | 2025 | Tlando |
| Almatica Pharma LLC | $20.52 | 2024 | Teriparatide |
| Acella Pharmaceuticals, LLC | $19.75 | 2024 | NP Thyroid 60 |
| Tolmar, INC. | $18.86 | 2025 | Jatenzo |
| Takeda Pharmaceuticals U.S.A., INC. | $18.80 | 2024 | Trintellix |
| Amneal Pharmaceuticals LLC | $18.61 | 2025 | Unithroid |
| Abbott Laboratories | $17.15 | 2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $17.09 | 2023 | Trelegy Ellipta |
| Shield Therapeutics INC | $15.95 | 2023 | Accrufer |
| Xeris Pharmaceuticals, INC. | $15.35 | 2025 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $15.31 | 2024 | Quviviq |
| Currax Pharmaceuticals LLC | $14.57 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Welker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.